Selected for the second round of research and development grants for fiscal year 2025 from the Mitsubishi UFJ Technology Development Foundation.

We have been selected for the "2025 Second Round Research and Development Grant" by the Mitsubishi UFJ Technology Development Foundation, which targets research and development of new technologies and products conducted by venture companies and other organizations.

Taking this as an opportunity, we will promote the development of angiogenesis therapy using ICS for critical lower limb ischemia .

https://www.mutech.or.jp/info/2025%e5%b9%b4%e5%ba%a6%e7%ac%ac2%e5%9b%9e%e7%a0%94%e7%a9%b6%e9%96%8b%e7%99%ba%e5%8a%a9%e6%88%90%e9%87%91%e4%ba%a4%e4%bb%98%e3%83%97%e3%83%ad%e3%82%b8%e3%82%a7%e3%82%af%e3%83%88%e6%b1%ba%e5%ae%9a/

A paper detailing the clinical trial of a physician-initiated clinical study using injectable cell scaffold (ICS-001) for comprehensive angiogenesis therapy for severe chronic lower limb ischemia (...

A paper detailing the details of a physician-initiated clinical trial of comprehensive, severe chronic lower limb ischemia (CLTI) angiogenesis therapy using Injectable cell scaffold (ICS-001), led by CEO Kenichi Yamahara, has been published in BMJ Open.

This clinical trial has now completed enrollment for all planned cases and is scheduled to conclude in July of next year. The trial results are expected to be released in the latter half of next year.

https://bmjopen.bmj.com/content/15/10/e107486.full

Certified as a venture company originating from Hyogo College of Medicine.

Our company has been certified as a venture company originating from Hyogo College of Medicine. Our CEO, Kenichi Yamahara, is affiliated with Hyogo College of Medicine, and the hospital is the clinical trial site for a physician-initiated clinical trial of comprehensive advanced chronic lower limb ischemia (CLTI) angiogenesis therapy using Injectable cell scaffold (ICS-001).